DK0460076T3 - Genetisk manipulerede immunoglobuliner - Google Patents

Genetisk manipulerede immunoglobuliner

Info

Publication number
DK0460076T3
DK0460076T3 DK90904172.5T DK90904172T DK0460076T3 DK 0460076 T3 DK0460076 T3 DK 0460076T3 DK 90904172 T DK90904172 T DK 90904172T DK 0460076 T3 DK0460076 T3 DK 0460076T3
Authority
DK
Denmark
Prior art keywords
genetically engineered
engineered immunoglobulins
immunoglobulins
preparing
found
Prior art date
Application number
DK90904172.5T
Other languages
Danish (da)
English (en)
Inventor
Maurizio Zanetti
Maurizio Sollazzo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23227670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0460076(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0460076T3 publication Critical patent/DK0460076T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK90904172.5T 1989-02-24 1990-02-23 Genetisk manipulerede immunoglobuliner DK0460076T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31614489A 1989-02-24 1989-02-24

Publications (1)

Publication Number Publication Date
DK0460076T3 true DK0460076T3 (da) 1996-03-25

Family

ID=23227670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90904172.5T DK0460076T3 (da) 1989-02-24 1990-02-23 Genetisk manipulerede immunoglobuliner

Country Status (9)

Country Link
US (3) US5508386A (de)
EP (1) EP0460076B1 (de)
JP (2) JP3355351B2 (de)
AT (1) ATE130765T1 (de)
CA (1) CA2047244C (de)
DE (2) DE69023900D1 (de)
DK (1) DK0460076T3 (de)
ES (1) ES2082850T3 (de)
WO (1) WO1990009804A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2082850T3 (es) * 1989-02-24 1996-04-01 Univ California Inmunoglobulinas preparadas geneticamente.
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1032420A4 (de) * 1997-11-14 2004-09-15 Euro Celtique Sa Immunoglobulin moleküle mit synthetischer variabler region und modifizierter spezifität
EP1042459A4 (de) * 1997-12-24 2003-07-23 Diatech Pty Ltd Bifunktionelle moleküle
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
EP1131354A4 (de) * 1998-11-13 2003-01-02 Euro Celtique Sa Impfstoffe zur empfängnisverhütung basierend auf antikörpern
WO2000050044A1 (en) * 1999-02-25 2000-08-31 Tai June Yoo Vaccine for house dust mite allergen using naked plasmid dna
DE60045707D1 (de) * 1999-04-27 2011-04-21 Nevagen Llc Somatische transgene immunisierung und darauf bezogene verfahren
WO2001026608A2 (en) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
HUP0300421A2 (hu) * 2000-03-31 2003-06-28 Purdue Research Foundation Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
WO2003002908A1 (en) * 2000-06-26 2003-01-09 Reveo, Inc. Backlight for a liquid crystal display having high light-recycling efficiency
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
JP2005523878A (ja) * 2001-09-28 2005-08-11 パーデュー・リサーチ・ファウンデーション リガンド・免疫原物質複合体を用いた処置方法
EP1485403A4 (de) * 2002-03-15 2007-08-08 Multicell Immunotherapeutics I Zusammensetzungen und verfahren zur einleitung bzw. verstärkung von antikörper- und haupthistokompatibilität-klasse-i- oder -klasse-ii-beschränkten t-zell-reaktionen unter anwendung von immunmodulierenden, nicht-codierenden rna-motiven
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (de) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
CA2481437A1 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
CN1662251B (zh) * 2002-04-19 2012-10-10 恩多塞特公司 佐剂增强的免疫应用
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス,インコーポレイテッド 細胞死及び/又はアポトーシスを誘導するための、選択されたrnaモチーフ
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
AU2006204705C1 (en) * 2005-01-13 2012-07-05 Novartis Vaccines And Diagnostics, Inc. ELISA assays using prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
EP1887084A1 (de) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
CN102083450A (zh) * 2008-04-30 2011-06-01 诺华有限公司 致病性构象异构体的分析
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003950A1 (fr) * 1982-11-30 1988-06-02 Marc Girard PEPTIDES COMPORTANT UN SITE IMMUNOGENE DU POLIOVIRUS ET ADNs CONTENANT DES SEQUENCES NUCLEOTIDIQUES CODANT POUR CES PEPTIDES
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
ES2082850T3 (es) * 1989-02-24 1996-04-01 Univ California Inmunoglobulinas preparadas geneticamente.
EP0580758A4 (de) * 1991-04-18 1995-04-05 Sinai School Medicine Rekombinante antikörper gegen menschlichen immunschwächevirus.

Also Published As

Publication number Publication date
ES2082850T3 (es) 1996-04-01
DE69023900T2 (de) 1996-07-04
EP0460076B1 (de) 1995-11-29
US5658762A (en) 1997-08-19
JP3357890B2 (ja) 2002-12-16
EP0460076A4 (en) 1992-08-05
JPH04503605A (ja) 1992-07-02
ATE130765T1 (de) 1995-12-15
US5583202A (en) 1996-12-10
WO1990009804A1 (en) 1990-09-07
DE69023900T4 (de) 1996-10-02
EP0460076A1 (de) 1991-12-11
US5508386A (en) 1996-04-16
CA2047244C (en) 2002-09-17
DE69023900D1 (de) 1996-01-11
JP2001190295A (ja) 2001-07-17
CA2047244A1 (en) 1990-08-25
JP3355351B2 (ja) 2002-12-09

Similar Documents

Publication Publication Date Title
DK0460076T3 (da) Genetisk manipulerede immunoglobuliner
DE3484664D1 (de) Rekombinante immunoglobulin-praeparate, verfahren zu ihrer herstellung, dna-sequenzen, expressionsvektoren und rekombinante wirkzellen hierfuer.
EP0699755A3 (de) Verfahren zur Herstellung modifizierter Immunoglobulinen mit reduzierter Immunogenität der variablen Domänen einer murinen Antikörpers, Zusammensetzungen die diese enthalten
SE9201331D0 (sv) Protein l och hybridproteiner daerav
DE69535719D1 (de) Fas-antigenbindender ligand
ATE196162T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
MX24652A (es) Compuestos de adn recombinante, vectores para la expresion de formas zimogenas de proteina c humana, celulas huesped transformadas y metodo para la prduccion recombinante de formas zimogenas de la proteina c humana.
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
DK1119630T3 (da) Nukleinsyrekonstruktioner til genetisk immunisering
DK0500659T3 (da) Monoklonale antistoffer.
SG95574A1 (en) Immunoreactive antigens of hepatitia e virus
DE68907735D1 (de) Genfragmente, die die variable region eines anti-hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.
ATE233811T1 (de) Blutplaettchen-gpiiia p1a1 und -p1a2-epitope, ihre herstellung und verwendung
DK218886A (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
NO883501D0 (no) Slekt-spesifikt listeria-antigen identifisert med monoklonale antistoffer.
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
DE69931282D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
MX24651A (es) Compuestos de adn recombinante, vectores de expresion de mutantes de glicosilacion de la proteina c humana, celulas huesped transformadas y metodo para la produccion recombinante de formas zimogenas de proteina c humana.
DE69923092D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
DE69927190D1 (de) Nukleinsäure die in menschliche Tumoren vervielfältigt sind, und damit zusammenhängende Materiale und Verfahren
ATE92102T1 (de) Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.